Developing first-in-class therapeutics for the treatment of cancer

ChromaCure logohromaCure

ChromaCure’s mission is to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology. The company is developing inhibitors of a novel target that is a key regulator of tumor initiation and progression, based on research conducted at the Laboratory of Stem Cells and Cancer of the Blanpain Laboratory, at the Université libre de Bruxelles (ULB).

Portrait of Mr Blanpain

Cédric Blanpain

Cédric Blanpain graduated as a Medical Doctor, and is board certified in internal medicine, from the Université libre de Bruxelles, Belgium (ULB). He conducted his PhD work in Prof. Marc Parmentier’s lab and his postdoc with Prof. Elaine Fuchs, Rockefeller University, USA. Cédric started his lab as assistant professor (chercheur qualifié) of the Belgian National Science Research Fund (FNRS) at the Interdisciplinary Research Institute (IRIBHM) of ULB. He is now full professor, Director of the Laboratory of Stem Cells and Cancer and WELBIO investigator. Cédric Blanpain has authored and published more than a hundred highly-cited papers in leading scientific journals, including Nature, Cell and Science. He received prestigious and highly competitive awards including the EMBO Young investigator award, ERC starting and ERC consolidator grants, the outstanding young investigator award of the International Society of Stem Cell Research, the Liliane Bettencourt award for life sciences and the Joseph Maisin Award. In 2012, Cédric Blanpain was selected by Nature as one of “The ten scientists that matter”. He is a member of EMBO, the Belgian Royal Academy of Medicine, and Academia Europaea.

Portrait of Mr Vakili

Jalal Vakili · CEO

Jalal Vakili, CEO, who has been involved in various aspects of drug development, with a focus on oncology, for the past 15 years. After completing his medical training and obtaining his PhD in Biomedical Sciences at ULB, Jalal went on to complete his post-doctoral work at Immunex Corporation in Seattle. He then worked in different start-ups in the Seattle area, before returning to Belgium in 2010 and joining Ablynx as a senior scientist. He joined the Jules Bordet Cancer Centre in Brussels in 2012 as director of research operations. Before joining ChromaCure, Jalal was Director of External Opportunities in the Oncology Centre for Innovation of the French pharmaceutical group Servier.

Marie Miglianico

Marie Miglianico

Marie Miglianico obtained her PhD degree at Maastricht University (NL) on a drug discovery project in the field of metabolic disorders. She later joined a startup company based in Nijmegen (NL) where she was responsible for several drug screening projects on malaria parasites and vectors. Marie started in November 2018 and is using her drug development expertise to contribute to discovery and assay development at Chromacure

Portrait of Ms Poelaert

Marylene Poelaert

Marylene Poelaert holds a Master in history and a Master in information science. She has been chief of staff for the President (Rector) of the Université Libre de Bruxelles for more than seven years. Marylène joined ChromaCure in December 2018.

Supporting organisations

As soon as the first wave of biotechnology rose in Europe, Wallonia saw an opportunity to enter this key sector. The Wallonia authorities started to help newborn companies to devise their strategic plans. Moreover, as these start-ups were facing a highly competitive environment, the risk of "sudden death" was great. This did not deter the entrepreneurial mind in Wallonia. On the contrary, biotechnology was chosen as a top priority sector to position the region at the forefront of European Bio-regions. The existing chemical and pharmaceutical companies provided the industrial expertise necessary to appreciate the results of the highly innovative research that was taking place in the universities. The life sciences sector could now enter a new phase of development. The ambition of many of these entrepreneurs has since turned to a rapid expansion and a shift of their activities towards the segments with the highest added values.

Theodorus invests in early stage projects based on proprietary disruptive technologies. Mostly dedicated to seed and early stage funding, Theodorus invests in Biotech, MedTech, Digital and Engineering applications. Theodorus has a priority access to ULB R&D outcome and spin-offs, but can also invest in projects outside ULB. The investment size varies from 250k€ (first investment) to 2.5M€ per company.

As soon as the first wave of biotechnology rose in Europe, Wallonia saw an opportunity to enter this key sector. The Wallonia authorities started to help newborn companies to devise their strategic plans. Moreover, as these start-ups were facing a highly competitive environment, the risk of "sudden death" was great. This did not deter the entrepreneurial mind in Wallonia. On the contrary, biotechnology was chosen as a top priority sector to position the region at the forefront of European Bio-regions. The existing chemical and pharmaceutical companies provided the industrial expertise necessary to appreciate the results of the highly innovative research that was taking place in the universities. The life sciences sector could now enter a new phase of development. The ambition of many of these entrepreneurs has since turned to a rapid expansion and a shift of their activities towards the segments with the highest added values.

Addresses

Billing
  • ChromaCure S.A.
  • 11, Granbonpré - Boite 5
  • 1435 Mt-St-Guibert – Belgium
  • VAT: BE06 9186 9227
Shipping
  • ChromaCure S.A.
  • Bâtiment H
  • 11, Granbonpré - Boite 5
  • 1435 Mt-St-Guibert – Belgium
Voice
  • Telephone
  • Skype
  • Other

Get In Touch

Please complete the form below.

© Copyright 2020 ChromaCure - All Rights Reserved